Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,247Revenue (TTM) $M943Net Margin (%)3.7Altman Z-Score3.1
Enterprise Value $M2,265EPS (TTM) $0.5Operating Margin %12.1Piotroski F-Score5
P/E(ttm)64.8Beneish M-Score-2.4Pre-tax Margin (%)5.6Higher ROA y-yN
Price/Book2.110-y EBITDA Growth Rate %--Quick Ratio2.1Cash flow > EarningsY
Price/Sales2.35-y EBITDA Growth Rate %-13.4Current Ratio2.6Lower Leverage y-yY
Price/Free Cash Flow26.5y-y EBITDA Growth Rate %38.4ROA % (ttm)1.8Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)3.5Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M73.8ROIC % (ttm)6.3Gross Margin Increase y-yN

Gurus Latest Trades with IPXL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
IPXLJoel Greenblatt 2016-03-31 Add0.16%$30.73 - $42.76
($35.27)
$ 30.44-14%Add 2317.15%478,620
IPXLNWQ Managers 2016-03-31 Reduce-0.01%$30.73 - $42.76
($35.27)
$ 30.44-14%Reduce -3.89%190,660
IPXLNWQ Managers 2015-12-31 Reduce-0.21%$34.53 - $44.76
($40.13)
$ 30.44-24%Reduce -66.75%198,378
IPXLJoel Greenblatt 2015-12-31 Buy 0.01%$34.53 - $44.76
($40.13)
$ 30.44-24%New holding19,801
IPXLNWQ Managers 2015-09-30 Reduce-0.07%$33.27 - $50.42
($45.1)
$ 30.44-33%Reduce -16.00%596,619
IPXLNWQ Managers 2015-06-30 Reduce-0.13%$44.44 - $51.31
($47.45)
$ 30.44-36%Reduce -24.12%710,302
IPXLGeorge Soros 2015-06-30 Sold Out -0.03%$44.44 - $51.31
($47.45)
$ 30.44-36%Sold Out0
IPXLGeorge Soros 2015-03-31 Buy 0.03%$30.2 - $47.3
($39.79)
$ 30.44-23%New holding61,206
IPXLJoel Greenblatt 2015-03-31 Sold Out -0.02%$30.2 - $47.3
($39.79)
$ 30.44-23%Sold Out0
IPXLNWQ Managers 2015-03-31 Add0.02%$30.2 - $47.3
($39.79)
$ 30.44-23%Add 3.32%936,127
IPXLMario Gabelli 2015-03-31 Sold Out -0.0011%$30.2 - $47.3
($39.79)
$ 30.44-23%Sold Out0
IPXLNWQ Managers 2014-12-31 Reduce-0.1%$23.63 - $32.75
($29.3)
$ 30.444%Reduce -30.25%906,043
IPXLJoel Greenblatt 2014-12-31 Add0.01%$23.63 - $32.75
($29.4)
$ 30.444%Add 136.17%79,609
IPXLMario Gabelli 2014-12-31 Buy $23.63 - $32.75
($29.3)
$ 30.444%New holding6,775
IPXLNWQ Managers 2014-09-30 Add0.08%$22.77 - $30.68
($25.55)
$ 30.4419%Add 31.90%1,298,995
IPXLJoel Greenblatt 2014-09-30 Buy 0.01%$22.77 - $30.68
($25.55)
$ 30.4419%New holding33,709
IPXLNWQ Managers 2014-06-30 Buy 0.3%$23.6 - $30.68
($26.93)
$ 30.4413%New holding984,841
IPXLJoel Greenblatt 2012-03-31 Sold Out -0.05%$18.64 - $24.37
($20.72)
$ 30.4447%Sold Out0
IPXLJoel Greenblatt 2011-12-31 Reduce-0.47%$16.53 - $20.75
($18.65)
$ 30.4463%Reduce -88.51%21,057
IPXLJoel Greenblatt 2011-09-30 Reduce-0.38%$15.26 - $21.56
($19.54)
$ 30.4456%Reduce -40.22%183,187
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

IPXL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


IPXL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SCHLOSSBERG MARK ASVP and General Counsel 2015-09-11Sell7,457$43.3-29.7view
NESTOR MICHAELPresident, Impax Pharm. 2015-09-10Sell5,000$43.56-30.12view
FLEMING NIGELDirector 2015-08-31Sell29,166$41.02-25.79view
MARKBREITER MICHAELDirector 2015-08-31Sell28,000$41.7-27view
BENET LESLIE ZDirector 2015-08-31Sell20,000$40.92-25.61view
SCHLOSSBERG MARK ASVP and General Counsel 2015-08-27Sell4,649$43.41-29.88view
TERRERI PETER RDirector 2015-08-27Sell4,833$43.93-30.71view
MARKBREITER MICHAELDirector 2015-08-26Sell19,399$42.24-27.94view
HSU LARRYDirector 2014-06-06Sell100,000$28.387.26view
TERRERI PETER RDirector 2014-05-27Sell3,000$288.71view

Quarterly/Annual Reports about IPXL:

News about IPXL:

Articles On GuruFocus.com
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' 3rd-Quarter Activity Nov 27 2015 
Kyle Bass Goes Fishing for These 3 New Holdings Nov 26 2015 
Alan Fournier's Highest Performing Stocks Jul 15 2015 
Alan Fournier's Most Heavily Weighted Trades In Q1 2015 May 28 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 

More From Other Websites
4 Low P/CF Stocks to Improve Your Value Investing Jul 22 2016
IMPAX LABORATORIES INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 21 2016
Impax Names Douglas S. Boothe President of Generics Division Jul 21 2016
Impax Laboratories, Inc. – Value Analysis (NASDAQ:IPXL) : July 19, 2016 Jul 19 2016
Coverage Initiated on Select Healthcare Stocks Jul 14 2016
Why the Teva Acquisition Proves It Is a Stock to Own for the Decade Jul 13 2016
Impax Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IPXL-US : July 13,... Jul 13 2016
Impax to Report Second Quarter 2016 Results on August 9, 2016 Jul 07 2016
Impax to Report Second Quarter 2016 Results on August 9, 2016 Jul 07 2016
[$$] Teva and Allergan Sell Generic Drugs to Impax In Latest Divestiture Jun 28 2016
Impax Laboratories, Inc. -- Moody's: Impax's Debt-Funded Acquisition of Generics Products is Credit... Jun 22 2016
Impax (IPXL) Stock Declines on Deal to Buy Generic Products Jun 22 2016
Stocks rise after Fed’s Janet Yellen takes a cautious tone on interest rates Jun 21 2016
Impax Buys Mystery Generics Portfolio From Teva, Allergan Jun 21 2016
Impax Buying Teva, Allergan Drugs, Clearing Way For Deal Closing Jun 21 2016
Impax Labs upgraded by BofA/Merrill Jun 21 2016
Impax (IPXL) Stock Tumbles on Teva, Allergan Generic Drug Deal Jun 21 2016
$586M deal: Impax buying generic drugs FTC asked Teva and Allergan to sell Jun 21 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)